BR112018072034A2 - compostos mic-1 e usos dos mesmos - Google Patents

compostos mic-1 e usos dos mesmos

Info

Publication number
BR112018072034A2
BR112018072034A2 BR112018072034-8A BR112018072034A BR112018072034A2 BR 112018072034 A2 BR112018072034 A2 BR 112018072034A2 BR 112018072034 A BR112018072034 A BR 112018072034A BR 112018072034 A2 BR112018072034 A2 BR 112018072034A2
Authority
BR
Brazil
Prior art keywords
compounds
mic
relates
amino acid
extension
Prior art date
Application number
BR112018072034-8A
Other languages
English (en)
Inventor
zhang Xujia
Gao Xiang
Guan Hongtao
Thøgersen Henning
Sass-Ørum Kristian
Fogh Iversen Lars
Nørgaard Per
Beck Jørgensen Sebastian
Tage Hansen Kristian
Wang Yi
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of BR112018072034A2 publication Critical patent/BR112018072034A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

a presente invenção refere-se a compostos mic-1. mais especificamente, refere-se a compostos compreendendo um polipeptídeo mic-1 e uma extensão de aminoácido n-terminal, em que referida extensão consiste em de 3 a 36 resíduos de aminoácidos e em que o composto tem um pi calculado inferior a 6,5. os compostos da invenção têm atividade de mic-1. a invenção refere-se também a composições farmacêuticas, compreendendo esses compostos e excipientes farmaceuticamente aceitáveis, bem como o uso médico dos compostos.
BR112018072034-8A 2016-05-24 2017-05-24 compostos mic-1 e usos dos mesmos BR112018072034A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/083104 2016-05-24
CN2016083104 2016-05-24
CNPCT/CN2016/103574 2016-10-27
CN2016103574 2016-10-27
PCT/EP2017/062583 WO2017202936A1 (en) 2016-05-24 2017-05-24 Mic-1 compounds and use thereof

Publications (1)

Publication Number Publication Date
BR112018072034A2 true BR112018072034A2 (pt) 2019-02-12

Family

ID=59009675

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072034-8A BR112018072034A2 (pt) 2016-05-24 2017-05-24 compostos mic-1 e usos dos mesmos

Country Status (18)

Country Link
US (3) US20190248852A1 (pt)
EP (1) EP3463412A1 (pt)
JP (1) JP7013390B2 (pt)
KR (1) KR102433503B1 (pt)
CN (1) CN109414471A (pt)
AU (1) AU2017269496B2 (pt)
BR (1) BR112018072034A2 (pt)
CA (1) CA3025251A1 (pt)
CL (1) CL2018003319A1 (pt)
CO (1) CO2018012258A2 (pt)
IL (1) IL262926A (pt)
MA (1) MA45113A (pt)
MX (1) MX2018014023A (pt)
PE (1) PE20190117A1 (pt)
PH (1) PH12018502465A1 (pt)
SA (1) SA518400460B1 (pt)
TW (1) TW201741333A (pt)
WO (1) WO2017202936A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
CN113527512A (zh) 2013-07-31 2021-10-22 美国安进公司 生长分化因子15(gdf-15)构建体
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
CN110072541B (zh) 2016-12-06 2023-05-02 圣文森特医院悉尼有限公司 肥胖和饮食失调的治疗
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019199685A1 (en) 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins
US20210340205A1 (en) 2018-08-10 2021-11-04 Novartis Ag Gfral extracellular domains and methods of use
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing Ql Biopharmaceutical Co Ltd FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
CN115244076B (zh) 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
AU3247699A (en) * 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
JP2010505437A (ja) 2006-10-13 2010-02-25 ノボ ノルディスク ヘルス ケア アーゲー 塩基性タンパク質タグに融合したプロセシング酵素
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
NZ628987A (en) * 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
CN102481331B (zh) * 2009-06-08 2017-09-22 阿穆尼克斯运营公司 葡萄糖调节多肽及其制备和使用方法
EP2830646B1 (en) * 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2015279525A1 (en) * 2014-06-24 2016-12-15 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
US10603359B2 (en) * 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途

Also Published As

Publication number Publication date
AU2017269496B2 (en) 2021-03-25
CA3025251A1 (en) 2017-11-30
US20210198331A1 (en) 2021-07-01
CN109414471A (zh) 2019-03-01
KR20190008290A (ko) 2019-01-23
PE20190117A1 (es) 2019-01-16
CO2018012258A2 (es) 2018-11-30
IL262926A (en) 2018-12-31
TW201741333A (zh) 2017-12-01
RU2018141829A (ru) 2020-06-25
MA45113A (fr) 2019-04-10
RU2018141829A3 (pt) 2020-10-07
CL2018003319A1 (es) 2019-02-01
US20230212245A1 (en) 2023-07-06
MX2018014023A (es) 2019-04-04
KR102433503B1 (ko) 2022-08-18
EP3463412A1 (en) 2019-04-10
SA518400460B1 (ar) 2022-09-21
PH12018502465A1 (en) 2019-04-08
US20190248852A1 (en) 2019-08-15
JP7013390B2 (ja) 2022-01-31
AU2017269496A1 (en) 2018-11-15
JP2019520333A (ja) 2019-07-18
WO2017202936A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
BR112016029848A2 (pt) proteínas de fusão mic-1 e utilizações das mesmas
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112017009405A2 (pt) composições antibióticas.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
WO2015191781A3 (en) Apelin polypeptides
MY195199A (en) EGF(A) Analogues with Fatty Acid Substituents
BR112015011179A2 (pt) composições aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112015018259A2 (pt) Redução de resposta pró-inflamatória
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
MY189021A (en) Peptides and uses therefor as antiviral agents
PH12021550090A1 (en) Composition comprising glycyrrhizin and cosmetic and pharmaceutical uses thereof
BR112015013223A2 (pt) composição farmacêutica
EA201890477A1 (ru) Инкапсулированная композиция финголимода

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B10A Cessation: cessation confirmed
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.23 NA RPI NO 2714 DE 10/01/2023 POR TER SIDO INDEVIDA.